Trial results

GLP-1s in Hip and Knee Arthroplasty

NCT07755085 on ClinicalTrials.gov · last registry update 2026-08-10

Registered but not yet open, with 100 participants planned. Due to report 1 June 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Incidence of Wound Complication after Joint Arthroplasty. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P4

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Nova Scotia Health Authority

Sponsor type

Other

Enrollment

100

Started

2026-10-01

Primary completion

2028-06-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Incidence of Wound Complication after Joint Arthroplasty

Conditions studied

Arthritis · Obesity & Overweight · GLP - 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.